Advanced Refractive: starts testing on drug to treat glaucoma

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Preclinical testing began on the novel glaucoma treatment licensed by Advanced Refractive Technologies, Inc. to assess the safety and efficacy of the compound before the start of human trials.

After six months of in vivo testing, phase one human trials of the compound are expected to begin.

The company said the compound is derived from monoclonal antibodies and works on Schlemm's Canal, a structure in the eye, to improve the outflow of fluid.

Unlike traditional daily glaucoma treatment, the new drug could require as few as two treatments per year, according to the San Clemente, Calif.-based ophthalmology development company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.